LONNER ANDERS 4
4 · VALEANT PHARMACEUTICALS INTERNATIONAL · Filed Sep 30, 2010
Insider Transaction Report
Form 4
LONNER ANDERS
Director
Transactions
- Disposition to Issuer
Common Stock
2010-09-28−12,766→ 0 total
Footnotes (1)
- [F1]8,881 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 24,844 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms and conditions. Remaining 3,885 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 8,145 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.